Home AbbVie AbbVie Walks Away from Inflammatory & Autoimmune Drug Dev Partnership

AbbVie Walks Away from Inflammatory & Autoimmune Drug Dev Partnership

168
0
AbbVie

EndPoints’ Natalie Grover reports that AbbVie and San Francisco-based Principia have parted ways. The two had signed a collaborative drug development deal which provided $15 million in upfront payments to the new publicly traded biotech.  See EndPoints for the story.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.